ArticleEuropean radiology2020
Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups.
Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.American journal of respiratory and critical care medicine · 2024Trial
- Meaningful thresholds for change in quantitative computed tomography-derived fibrosis extent in idiopathic pulmonary fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Non-Resolving Repair in Idiopathic Pulmonary Fibrosis: From Failed Cellular Transitions to Architectural Lock-In.International journal of molecular sciences · 2026Review
- A Spatiotemporal Transformer Framework on 4D-CT for Early Prediction of Progressive Pulmonary Fibrosis.Journal of imaging informatics in medicine · 2026Article
- Article
- e-Lung computed tomography biomarkers are associated with outcomes in fibrotic interstitial lung diseases.ERJ open research · 2026Article
- A Quantitative Imaging Measure of Progressive Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2025Article
- Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.American journal of respiratory and critical care medicine · 2024Article
- Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.American journal of respiratory and critical care medicine · 2024Article
- Disease progression in idiopathic pulmonary fibrosis under anti-fibrotic treatment.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2023Article
- Generative Adversarial Network-Based Image Conversion Among Different Computed Tomography Protocols and Vendors: Effects on Accuracy and Variability in Quantifying Regional Disease Patterns of Interstitial Lung Disease.Korean journal of radiology · 2023Article
- Recent Advances of Artificial Intelligence Applications in Interstitial Lung Diseases.Diagnostics (Basel, Switzerland) · 2023Review
- Pulmonary vessel volume in idiopathic pulmonary fibrosis compared with healthy controls aged > 50 years.Scientific reports · 2023Article
- HyperpolarizedRadiology · 2022Article
- Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.Nature medicine · 2022Article
- Towards Treatable Traits for Pulmonary Fibrosis.Journal of personalized medicine · 2022Review
- Quantitative Computed Tomography: What Clinical Questions Can it Answer in Chronic Lung Disease?Lung · 2022Review
- Influence of CT Image Matrix Size and Kernel Type on the Assessment of HRCT in Patients with SSC-ILD.Diagnostics (Basel, Switzerland) · 2022Article
- Quantitative analysis of high-resolution computed tomography features of idiopathic pulmonary fibrosis: a structure-function correlation study.Quantitative imaging in medicine and surgery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveHigh-resolution computed tomography (HRCT) plays an indispensable role in the diagnosis of idiopathic pulmonary fibrosis (IPF). Due to unpredictability in progression and the short median survival of 2-5 years, it is critical to delineate the patients with rapid progression. The aim is to evaluate the predictability of IPF progression using the early quantitative changes.
methodsAutomated texture-based quantitative lung fibrosis (QLF) was calculated from the anonymized HRCT. Two datasets were collected retrospectively: (1) a pilot study of 35 subjects with three sequential scans (baseline and 6 and 12 months) to obtain a threshold, where visual assessments were stable at 6 months but worsened at 12 months; (2) 157 independent subjects to test the threshold. Landmark Cox regressions were used to compare the progression-free survival (PFS) defined by pulmonary function using the threshold from the early changes in QLF. C-indexes were reported as estimations of the concordance of prediction.
resultsA threshold of 4% QLF change at 6 months corresponded to the mean change that worsened on HRCT visually at 12 months from the pilot study. Using the threshold, significant differences were found in the independent dataset (hazard ratio (HZ) = 5.92, p = 0.001 by Cox model, C-index = 0.71 at the most severe lobe; and HZ = 3.22, p = 0.012, C-index = 0.68 in the whole lung). Median PFS was 11.9 months for subjects with ≥ 4% changes, whereas median PFS was greater than 18 months for subjects with < 4% changes at the most severe lobe.
conclusionEarly structural changes on HRCT using a quantitative score can predict progression in lung function. KEY POINTS: • Changes on HRCT using quantitative texture-based scores can play a pivotal role for providing information and an aid tool for timely management decision for patients with IPF. • Quantitative changes on HRCT of 4% or more, which matched 6-month prior changes with visual assessment of worsening, can play a pivotal role for providing prediction of clinical progression by 3-5 folds higher in the next incidence, compared with those of subjects with less than 4% changes. • Early structural changes of 4% or more in a paired HRCT scans derived by quantitative scores can predict the progression in lung function in 1-2 years in subjects with IPF, which is critical information for timely management decision for subjects with IPF where the median survival is 2 to 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.